Roger Bendelac was named Chief Executive Officer of Drugs Made In America Acquisition II Corp. As of November 14, 2026, Drugs Made In America Acquisition II Corp. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 6, 2026, naming 1 appointment (Form 8-K, March 6, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Drugs Made In America Acquisition II Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Drugs Made In America Acquisition II Corp. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-06. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Drugs Made In America Acquisition II Corp. files it.
Also on the record for Drugs Made In America Acquisition II Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G, by KARPUS MANAGEMENT, INC. | 5.18% of the class | 5%+ stakes | Source |
| October 2, 2025 | Stake report, Schedule 13D, by Drugs Made In America Acquisition II LLC | 10.2% of the class | 5%+ stakes | Source |
| September 25, 2025 | IPO filing, Form 424B4 | $10 a share | IPO filings | Source |
| September 16, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 15, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 5, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| July 21, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs Drugs Made In America Acquisition II Corp. now and the warning signs.
Free to see. No signup.
Keep reading
More on Drugs Made In America Acquisition II Corp. and the records around it.
Drugs Made In America Acquisition II Corp. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- KARPUS MANAGEMENT, INC. also filed stake reports on 96 other companies: ABRDN AUSTRALIA EQUITY FUND, INC. (Nov 2026), ACP Holdings Acquisition Corp. (Nov 2026), Future Money Acquisition Corp. (Nov 2026)
Watch Drugs Made In America Acquisition II Corp.
Get an email when Drugs Made In America Acquisition II Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Drugs Made In America Acquisition II Corp.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Drugs Made In America Acquisition II Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Drugs Made In America Acquisition II Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-06 | In | Chief Executive Officer | 8-K, 2026-03-06 |
Who leads Drugs Made In America Acquisition II Corp., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Roger Bendelac, appointed (filed 2026-03-06).
New leaders reset buying decisions — get the Full Report on Drugs Made In America Acquisition II Corp.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Drugs Made In America Acquisition II Corp., with the record behind each one.
Find candidates like Chief Executive Officer at Drugs Made In America Acquisition II Corp.Every change, in the filing's words
Appointed: Roger Bendelac, Chief Executive Officer
On February 28, 2026, Roger Bendelac was appointed to the position of Chief Executive Officer of the Company to be effective as of the date of Ms. Stockwell's resignation as the Company's Chief Executive Officer.
- Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- As previously reported in the Quarterly Report on Form 10-Q for the period ended September 30, 2025, for Drugs Made In America Acquisition II Corp. (the "Company"), between the completion of the Company's initial public offering on September 26, 2025 and September 30, 2025, the sponsor to the Company (the "Sponsor") withdrew an aggregate amount of $1,100,000 (the "Withdrawal") from the Company's working capital account (the "Account").
- Of the aggregate Withdrawal amount, $325,000 was used to repay an outstanding working capital note (the "Note") to the Sponsor and $208,000 was used to repay other offering costs and expenses to the Sponsor, which amounts, in aggregate, were above the amounts previously advanced by the sponsor to the Company under the Note.
- An additional amount of $566,269 also appeared as an overpayment to the Sponsor by the Company and between September 30, 2025 and December 31, 2025, the Sponsor withdrew additional funds from the Account, in an amount no less than $200,000 to pay for expenses unrelated to the Company (the "Overpayment Amount").
Tools for this story
Each opens in a new tab, filled in for Drugs Made In America Acquisition II Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
